Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC
Adding immunotherapy before chemotherapy in lung cancer works as well as adding it after, letting doctors choose the simpler approach.
This propensity-matched retrospective study of 265 stage III NSCLC patients shows that adding ICI as induction before chemoradiotherapy provides equivalent survival outcomes to consolidation-only ICI, suggesting the simpler consolidation-only approach remains appropriate standard of care. The findings may inform treatment sequencing in settings where induction ICI is offered, though prospective validation is needed.
What the study was
- Study design
- Retrospective cohort study with propensity score matching (1:1), 2 centers China, 2019-2023
- Population
- Unresectable stage III NSCLC patients receiving chemoradiotherapy combined with immune checkpoint inhibitors, n=265 (153 consolidation-only, 112 induction+consolidation), PSM n=each arm
- Sample size
- 265
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Oncoimmunology
Why it surfaced
Directly addresses a clinically relevant sequencing question in the high-volume setting of stage III NSCLC. Equivalent outcomes support simpler/lower-cost consolidation-only approach. PSM reduces confounding, though retrospective.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.